

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**Form 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16  
UNDER THE SECURITIES EXCHANGE ACT OF 1934**

For the month of November 2022.

Commission File Number: 001-40065

**IM Cannabis Corp.**

(Exact Name of Registrant as Specified in Charter)

**Kibbutz Glil Yam, Central District, Israel 4690500**

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F  Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): \_\_\_\_

**Note:** Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): \_\_\_\_

**Note:** Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant's "home country"), or under the rules of the home country exchange on which the registrant's securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant's security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**IM CANNABIS CORP.**  
(Registrant)

Date: November 17, 2022

By: /s/ Oren Shuster

Name: Oren Shuster

Title: Chief Executive Officer and Director

---

**EXHIBIT INDEX**

- [99.1](#) [News Release dated November 17, 2022](#)
  - [99.2](#) [FORM 51-102F3 Material Change Report dated November 17, 2022](#)
- 
-

## IM Cannabis Common Shares Commence Trading on Consolidated Basis After 1 for 10 Reverse Stock Split

GLIL YAM, Israel, November 17, 2022 -- IM Cannabis Corp. (“**IMC**” or the “**Company**”) (NASDAQ: IMCC) (CSE: IMCC), an international medical cannabis company, announced today that further to the press release dated November 14, 2022, all of its issued and outstanding common shares (“**Common Shares**”) began trading on the Canadian Securities Exchange (the “**CSE**”) and the Nasdaq Capital Market (“**NASDAQ**”) on a post-consolidation basis on November 17, 2022.

On November 14, 2022, the Company announced that the Common Shares would be consolidated on the basis of one (1) post-consolidation Common Share for each ten (10) pre-consolidation Common Shares (the “**Share Consolidation**”). The Company’s shareholders approved the Share Consolidation at the Company’s annual general and special meeting of shareholders held on October 20, 2022. The Share Consolidation is intended to increase the trading price of the Common Shares to enable the Company to satisfy the minimum bid price requirement for continued listing on the NASDAQ. The Company’s post-Share Consolidation Common Shares will continue to trade on the CSE and NASDAQ under the same symbol, “IMCC”. The new CUSIP and ISIN numbers for the post-consolidated Common Shares are 44969Q307 and CA44969Q3070, respectively.

The Share Consolidation has reduced the number of existing Common Shares from 75,695,325 Common Shares to approximately 7,569,526 Common Shares, subject to adjustments for rounding purposes. A letter of transmittal was sent by mail to registered shareholders advising that the Share Consolidation has taken effect. The letter instructs registered shareholders on how to exchange their share certificates or Direct Registration System (“**DRS**”) statements evidencing their pre-Share Consolidation Common Shares for new share certificates or DRS that represent the number of post-Share Consolidation Common Shares to which they are entitled. Following the Share Consolidation, any fractional interest in a Common Share that is less than 0.5 of a Common Share will be rounded down to the nearest whole Common Share and any fractional interest in a Common Share that is 0.5 or greater of a Common Share will be rounded up to the nearest whole Common Share. Proportionate adjustments will be made to the Company’s outstanding securities that are convertible, exchangeable or exercisable for Common Shares.

Beneficial shareholders holding their Common Shares through an intermediary may be subject to different procedures for obtaining their post-Share Consolidation Common Shares. If you have questions in this regard, you are encouraged to contact your intermediary.

### About IM Cannabis Corp.

IM Cannabis (NASDAQ: IMCC) (CSE: IMCC) is an international cannabis company that operates in the three largest federally legal markets, providing premium products to medical patients in Israel and Germany, and to adult-use recreational consumers in Canada. The Company leverages a transnational ecosystem powered by a unique data-driven approach and a globally sourced product supply chain. With an unwavering commitment to responsible growth and compliance with the strictest regulatory environments, the Company strives to amplify its commercial and brand power to become a global high-quality cannabis player.

The IMC ecosystem operates in Israel through its commercial relationship with Focus Medical Herbs Ltd. (“**Focus Medical**”), which imports, and distributes cannabis to medical patients, leveraging years of proprietary data and patient insights. The Company also operates medical cannabis retail pharmacies, online platforms, distribution centers and logistical hubs in Israel that enable the safe delivery and quality control of IM Cannabis products throughout the entire value chain. In Germany, the IMC ecosystem operates through Adjupharm GmbH, where it also distributes cannabis to pharmacies to medical cannabis patients. In Canada, IMC operates through Trichome Financial and its wholly-owned subsidiaries Trichome JWC Acquisition Corp. and MYM Nutraceuticals Inc., where it cultivates and processes cannabis for the adult-use market at its Ontario and Nova Scotia facilities under the WAGNERS and Highland Grow brands. For more information, please visit [www.imcannabis.com](http://www.imcannabis.com).

### Company Contact:

Maya Lustig, Director Investor & Public Relations  
IM Cannabis  
+972-54-677-8100  
[maya.l@imcannabis.com](mailto:maya.l@imcannabis.com)

Oren Shuster, CEO  
IM Cannabis Corp.  
+972-77-3603504  
[info@imcannabis.com](mailto:info@imcannabis.com)

---

---

FORM 51-102F3

**MATERIAL CHANGE REPORT**

***Item 1 — Name and Address of Company***

IM Cannabis Corp. (the “**Company**”)  
Suite 2300 – 550 Burrard Street  
Vancouver, BC, Canada, V6C 2B5

***Item 2 — Date of Material Change***

November 17, 2022

***Item 3 — News Release***

A news release disclosing the material change was issued by the Company through the services of Canadian Newswire on November 17, 2022 and subsequently filed on the Company’s SEDAR profile at [www.sedar.com](http://www.sedar.com).

***Item 4 — Summary of Material Change***

On November 17, 2022, the Company completed the consolidation of its issued and outstanding common shares (the “**Common Shares**”) on the basis of one (1) post-consolidation Common Share for each ten (10) pre-consolidation Common Shares (the “**Share Consolidation**”).

***Item 5 — Full Description of Material Change***

***5.1 — Full Description of Material Change***

On November 17, 2022, the Company consolidated its Common Shares on the basis of one (1) post-Share Consolidation Common Share for each ten (10) pre-Share Consolidation Common Shares. The Common Shares began trading on the Canadian Securities Exchange (the “**CSE**”) and the Nasdaq Capital Market (“**NASDAQ**”) on a post-Share Consolidation basis on November 17, 2022.

The Share Consolidation is intended to increase the trading price of the Common Shares to enable the Company to satisfy the minimum bid price requirement for continued listing on the NASDAQ. The Company’s post-Share Consolidation Common Shares will continue to trade on the CSE and NASDAQ under the same symbol, “IMCC”. The new CUSIP and ISIN numbers for the post-consolidated Common Shares are 44969Q307 and CA44969Q3070, respectively.

The Share Consolidation has reduced the number of existing Common Shares from 75,695,325 Common Shares to approximately 7,569,526 Common Shares, subject to adjustments for rounding purposes. Following the Share Consolidation, any fractional interest in a Common Share that is less than 0.5 of a Common Share will be rounded down to the nearest whole Common Share and any fractional interest in a Common Share that is 0.5 or greater of a Common Share will be rounded up to the nearest whole Common Share. Proportionate adjustments will be made to the Company’s outstanding securities that are convertible, exchangeable or exercisable for Common Shares.

The Company’s shareholders approved the Share Consolidation at the Company’s annual general and special meeting of shareholders held on October 20, 2022.

---

*5.2 — Disclosure for Restructuring Transactions*

Not applicable.

*Item 6 — Reliance on subsection 7.1(2) of National Instrument 51-102*

Not applicable.

*Item 7 — Omitted Information*

Not applicable.

*Item 8 — Executive Officer*

Yael Harrosh  
Chief Legal and Operations Officer  
+972-54-6687515

*Item 9 — Date of Report*

November 17, 2022.